73113-90-3
Chemical Structure
Hydroxyrubicin
- CAS No.: 73113-90-3
- Formula:C27H28O12
- Molecular Weight:544.50
IUPAC Name: (8S,10S)-10-(((2R,4S,5S,6S)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
InChIKey: HEQRYQONNHFDHG-TZSSRYMLSA-N
SMILES: OC1=C2C([C@H](C[C@@](C(CO)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)O)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O
Biological Activity: Hydroxyrubicin is an antitumor agent. Hydroxyrubicin can induce topoisomerase II-mediated DNA cleavage. Hydroxyrubicin induces DNA unwinding. Hydroxyrubicin has a significant inhibitory effect on tumor cells. Hydroxyrubicin can be used for the study of Multidrug-resistant (MDR) leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hydroxyrubicin | Hydroxyrubicin is an antitumor agent. Hydroxyrubicin can induce topoisomerase II-mediated DNA cleavage. Hydroxyrubicin induces DNA unwinding. Hydroxyrubicin has a significant inhibitory effect on tumor cells. Hydroxyrubicin can be used for the study of Multidrug-resistant (MDR) leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Solary E, et al. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance[J]. International journal of cancer, 1994, 58(1): 85-94.
- [2]. Priebe W, et al. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs. 1993 Feb;4(1):37-48. [Content Brief]
Keywords
